程序性死亡受体1抑制剂联合化疗治疗食管癌的临床疗效  

Clinical efficacy of programmed cell death 1 inhibitor combined with chemotherapy in the treatment of esophageal cancer

作　　者：冯潇[1] 王博[1] 张江浩 李元颖 FENG Xiao;WANG Bo;ZHANG Jianghao;LI Yuanying(Department of Digestive Oncology,Nanyang Central Hospital,Nanyang 473000,He’nan,China)

机构地区：[1]南阳市中心医院消化道肿瘤科,河南南阳4730000

出　　处：《癌症进展》2025年第3期317-320,共4页Oncology Progress

基　　金：吴阶平医学基金会临床科研专项资助基金(320.6750.2020-12-42)。

摘　　要：目的 探讨程序性死亡受体1(PD-1)抑制剂联合化疗治疗食管癌的临床疗效。方法 依据治疗方法的不同将78例食管癌患者分为对照组40例和观察组38例,对照组患者接受奈达铂+白蛋白结合型紫杉醇治疗,观察组患者在此基础上联合PD-1抑制剂信迪利单抗治疗。比较两组患者的临床疗效、肿瘤标志物[糖类抗原125(CA125)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)、癌胚抗原(CEA)]水平及不良反应发生情况。结果观察组患者的疾病控制率为76.32%,高于对照组患者的52.50%,差异有统计学意义(P﹤0.05)。治疗后,两组患者CA125、CYFRA21-1、CEA水平均低于本组治疗前,观察组患者CA125、CYFRA21-1、CEA水平均低于对照组,差异均有统计学意义(P﹤0.05)。两组患者骨髓抑制、胃肠道症状、头晕发生率比较,差异均无统计学意义(P﹥0.05)。结论 PD-1抑制剂联合化疗治疗食管癌患者的效果显著,可降低血清肿瘤标志物水平,且不增加不良反应发生风险。Objective To evaluate the clinical efficacy of programmed cell death 1(PD-1)inhibitor combined with chemotherapy in the treatment of esophageal cancer.Method According to different treatment methods,78 patients with esophageal cancer were divided into control group(n=40)and observation group(n=38).The control group received nedaplatin+albumin bound paclitaxel treatment,while the observation group received PD-1 inhibitor sintilimab treatment on this basis.The clinical efficacy,tumor markers[carbohydrate antigen 125(CA125),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA)]levels,and incidence of adverse reactions were compared between the two groups.Result The disease control rate of the observation group was 76.32%,which was higher than 52.50%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CA125,CYFRA21-1,and CEA in both groups were lower than those before treatment,the levels of CA125,CYFRA21-1,and CEA in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There were no statistically significant differences in the incidence of bone marrow suppression,gastrointestinal symptoms,and dizziness between the two groups(P>0.05).Conclusion The combination of PD-1 inhibitors combined with chemotherapy has significant effect on the treatment of esophageal cancer,reduce serum tumor marker levels,and without increasing the risk of adverse reactions.

关 键 词：食管癌 程序性死亡受体1 信迪利单抗 奈达铂 白蛋白结合型紫杉醇 

分 类 号：R735.1[医药卫生—肿瘤]